<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382848</url>
  </required_header>
  <id_info>
    <org_study_id>00001746</org_study_id>
    <nct_id>NCT02382848</nct_id>
  </id_info>
  <brief_title>Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD</brief_title>
  <official_title>Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out how effective Prazosin is in the treatment of bulimic
      patients experiencing distressing nightmares using subjective and objective measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To the investigators knowledge, there is no treatment trial for prazosin use in patients with
      bulimia nervosa struggling with nightmares, looking at either objective or subjective
      measures. The investigators plan to probe the effectiveness of prazosin in bulimic patients
      experiencing nightmares due to PTSD using both subjective and objective measures in order to
      improve future clinical care. The effects of prazosin on decreasing nightmares and bulimic
      symptoms on subjective scales and effects on sleep architecture using objective polysomnogram
      (PSG) measurements will help inform targeted psychopharmacologic and psychotherapeutic
      strategies to improve clinical care of bulimic patients struggling with distressing dreams
      secondary to PTSD. This study will be performed in two phases. Phase A will involve eight
      participants who will be tested using subjective scales (mentioned below). If Phase A data
      analysis leads to detection of a signal of efficacy 2 more participants will be recruited to
      participate in phase B of this trial using objective polysomnogram measurements. The results
      from this project will aid in establishing a fully powered clinical trial for treatment of
      nightmares in bulimic patients and improve outcomes in this high risk population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in frequency of nightmares</measure>
    <time_frame>3 weeks</time_frame>
    <description>Subjective measures will be used to determine if there is a decrease in frequency of nightmares in patients undergoing drug intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in Rapid Eye Movement (REM) Density &amp; normalization of REM disruptions</measure>
    <time_frame>3 weeks</time_frame>
    <description>PSG will be used in 2 participants to determine if there is a decrease in REM density in patients undergoing drug intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in bulimia symptoms</measure>
    <time_frame>3 weeks</time_frame>
    <description>Rating scales will be used to determine if there is a decrease in bulimia symptoms among participants undergoing drug intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in total CAPS score (PTSD)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Rating scales and patient interview will be used to determine if there is a decrease in PTSD Symptoms among participants undergoing drug intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in depressed mood &amp; self-harm thoughts</measure>
    <time_frame>3 weeks</time_frame>
    <description>Rating scales and patient interview will be used to determine if there is a decrease in depressed mood &amp; self-harm thoughts among participants undergoing drug intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <condition>Bulimia Nervosa</condition>
  <arm_group>
    <arm_group_label>Pazosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given for a 3 consecutive week period during the 7 week study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin</intervention_name>
    <description>A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.</description>
    <arm_group_label>Pazosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (sugar pill) is used for 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-45

          -  Clinical diagnosis of Bulimia Nervosa with complaint of nightmares secondary to PTSD

        Exclusion Criteria:

          -  Restless leg syndrome

          -  Narcolepsy

          -  Sleep Apnea

          -  Neurological disorders

          -  Pregnancy

          -  cardiac abnormalities

          -  significant electrolyte abnormalities

          -  Use of steroids, beta blockers, prazosin

          -  Alcohol/substance abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fauzia Mahr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fauzia Mahr, MD</last_name>
    <phone>717 531-8133</phone>
    <email>fmahr@hmc.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Criley, BA</last_name>
    <phone>717 531-4123</phone>
    <email>ccriley@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine, Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fauzia Mahr, MD</last_name>
      <phone>717-531-8133</phone>
      <email>fmahr@mnc.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Criley, BA</last_name>
      <phone>717 531-4123</phone>
      <email>ccriley@psu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aurora RN, Zak RS, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, Maganti RK, Ramar K, Kristo DA, Bista SR, Lamm CI, Morgenthaler TI; Standards of Practice Committee; American Academy of Sleep Medicine. Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med. 2010 Aug 15;6(4):389-401.</citation>
    <PMID>20726290</PMID>
  </reference>
  <reference>
    <citation>Singareddy R, Krishnamurthy VB, Vgontzas AN, Fernandez-Mendoza J, Calhoun SL, Shaffer ML, Bixler EO. Subjective and objective sleep and self-harm behaviors in young children: a general population study. Psychiatry Res. 2013 Oct 30;209(3):549-53. doi: 10.1016/j.psychres.2013.03.036. Epub 2013 Apr 23.</citation>
    <PMID>23623452</PMID>
  </reference>
  <reference>
    <citation>Dansky BS, Brewerton TD, Kilpatrick DG, O'Neil PM. The National Women's Study: relationship of victimization and posttraumatic stress disorder to bulimia nervosa. Int J Eat Disord. 1997 Apr;21(3):213-28.</citation>
    <PMID>9097195</PMID>
  </reference>
  <reference>
    <citation>Mitchell KS, Mazzeo SE, Schlesinger MR, Brewerton TD, Smith BN. Comorbidity of partial and subthreshold ptsd among men and women with eating disorders in the national comorbidity survey-replication study. Int J Eat Disord. 2012 Apr;45(3):307-15. doi: 10.1002/eat.20965. Epub 2011 Oct 19.</citation>
    <PMID>22009722</PMID>
  </reference>
  <reference>
    <citation>Gleaves DH, Eberenz KP, May MC. Scope and significance of posttraumatic symptomatology among women hospitalized for an eating disorder. Int J Eat Disord. 1998 Sep;24(2):147-56.</citation>
    <PMID>9697013</PMID>
  </reference>
  <reference>
    <citation>Bicanic IA, Postma RM, Sinnema G, De Roos C, Olff M, Van Wesel F, Van de Putte EM. Salivary cortisol and dehydroepiandrosterone sulfate in adolescent rape victims with post traumatic stress disorder. Psychoneuroendocrinology. 2013 Mar;38(3):408-15. doi: 10.1016/j.psyneuen.2012.06.015. Epub 2012 Aug 4.</citation>
    <PMID>22867760</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Tsigos C, Bixler EO, Stratakis CA, Zachman K, Kales A, Vela-Bueno A, Chrousos GP. Chronic insomnia and activity of the stress system: a preliminary study. J Psychosom Res. 1998 Jul;45(1):21-31.</citation>
    <PMID>9720852</PMID>
  </reference>
  <reference>
    <citation>Lester NA, Keel PK, Lipson SF. Symptom fluctuation in bulimia nervosa: relation to menstrual-cycle phase and cortisol levels. Psychol Med. 2003 Jan;33(1):51-60.</citation>
    <PMID>12537036</PMID>
  </reference>
  <reference>
    <citation>Ross RJ, Gresch PJ, Ball WA, Sanford LD, Morrison AR. REM sleep inhibition by desipramine: evidence for an alpha-1 adrenergic mechanism. Brain Res. 1995 Dec 1;701(1-2):129-34.</citation>
    <PMID>8925274</PMID>
  </reference>
  <reference>
    <citation>Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008 Mar 15;63(6):629-32. Epub 2007 Sep 14.</citation>
    <PMID>17868655</PMID>
  </reference>
  <reference>
    <citation>Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A, Nofzinger EA. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans. J Psychosom Res. 2012 Feb;72(2):89-96. doi: 10.1016/j.jpsychores.2011.11.010. Epub 2011 Dec 20.</citation>
    <PMID>22281448</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Fauzia Mahr, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Eating Disorders</keyword>
  <keyword>Bulimia Nervosa</keyword>
  <keyword>Nightmares</keyword>
  <keyword>Post Traumatic Stress Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

